Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00015444
Other study ID # 010145
Secondary ID 01-N-0145
Status Completed
Phase
First received
Last updated
Start date May 1, 2001
Est. completion date April 24, 2019

Study information

Verified date April 24, 2019
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective:

The objectives of this protocol are:

to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols,

to characterize the natural history of neurodegenerative disorders with corticospinal neuron degeneration,

to investigate proposed etiologies, risk factors, and biomarkers for the development of these disorders and for disease progression

Study Population:

240 patients with adult-onset progressive spasticity with a diagnosis of primary lateral sclerosis or related upper motor neuron disorder

Design:

Patients who have been referred by physicians for primary lateral sclerosis will undergo a screening evaluation at the first visit. The screening visit will include review of outside medical records, neurological examination, and diagnostic testing to determine possible causes of spasticity. Patients fulfilling the clinical criteria for primary lateral sclerosis by history or examination will be followed to determine the natural history of this disorder. Measures of motor and cognitive function will be made at baseline and follow-up visits to follow clinical progression. Magnetic resonance imaging will be carried out to determine if imaging changes occur over time. Patients identified in this protocol who are eligible for other research protocols will be invited to participate in additional protocols.

Outcome Measures:

Clinical progression will be documented by measures of finger-tapping, timed gait, speech. The association between clinical progression and MRI measures will be assessed as a secondary outcome....


Description:

Objective:

The objectives of this protocol are:

- to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols,

- to characterize the natural history of neurodegenerative disorders with corticospinal neuron degeneration,

- to investigate proposed etiologies, risk factors, and biomarkers for the development of these disorders and for disease progression

Study Population:

240 patients with adult-onset progressive spasticity with a diagnosis of primary lateral sclerosis or related upper motor neuron disorder

Design:

Patients who have been referred by physicians for primary lateral sclerosis will undergo a screening evaluation at the first visit. The screening visit will include review of outside medical records, neurological examination, and diagnostic testing to determine possible causes of spasticity. Patients fulfilling the clinical criteria for primary lateral sclerosis by history or examination will be followed to determine the natural history of this disorder. Measures of motor and cognitive function will be made at baseline and follow-up visits to follow clinical progression. Magnetic resonance imaging will be carried out to determine if imaging changes occur over time. Blood samples may be collected for measurement of potential etiologies of PLS, including risk factor genes. Patients identified in this protocol who are eligible for other research protocols will be invited to participate in additional protocols.

Outcome Measures:

Clinical progression will be documented by measures of finger-tapping, timed gait, speech. The association between clinical progression and MRI measures will be assessed as a secondary outcome.


Recruitment information / eligibility

Status Completed
Enrollment 189
Est. completion date April 24, 2019
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - INCLUSION CRITERIA:

- Age 18 years of age or older

- Adult onset of progressive spasticity

- No family history of a similar disorder

- Able to provide consent or with a legally-authorized representative who can provide consent

EXCLUSION CRITERIA:

- History of stroke, cerebral palsy, traumatic brain injury or other known etiology of spasticity

- Non-neurological disorders producing muscle stiffness, such as fasciitis or rheumatological conditions

- Disorders in which pain limits the ability to move muscles, such as fibromyalgia or complex regional pain syndromes

- Profound weakness of voluntary movement

- Inability to travel to NIH

- Anticoagulation will be an exclusion for needle EMG studies

- Implanted devices or metal fragments in the brain or spinal cord will be an exclusion for MRI scanning

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Auger RG. AAEM minimonograph #44: diseases associated with excess motor unit activity. Muscle Nerve. 1994 Nov;17(11):1250-63. Review. — View Citation

Bentley S. Exercise-induced muscle cramp. Proposed mechanisms and management. Sports Med. 1996 Jun;21(6):409-20. Review. — View Citation

Leclerc KM, Landry FJ. Benign nocturnal leg cramps. Current controversies over use of quinine. Postgrad Med. 1996 Feb;99(2):177-8, 181-4. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The primary outcome of this protocol is to document the natural history of clinical progression in PLS, defined as the change in clinical measures of movement speed over time: finger tapping, timed gait, and time to read a standard passage.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Active, not recruiting NCT02567136 - Imaging Biomarkers in ALS
Recruiting NCT05204017 - Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Completed NCT00324454 - Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease Phase 2
Completed NCT01143428 - Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study
Recruiting NCT06320444 - Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease
Not yet recruiting NCT06315673 - Digital Assessment of Speech and Fine Motor Control in ALS
Completed NCT03560661 - Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)
Recruiting NCT04875416 - Phenotype, Genotype and Biomarkers 2
Active, not recruiting NCT03912987 - TRIAL READY (Clinical Trial Readiness)
Withdrawn NCT05830214 - Digital Smartwatch Measurements as Potential Biomarkers for Remote Disease Tracking in ALS
Recruiting NCT03489278 - Clinical Procedures to Support Research in ALS
Completed NCT02852278 - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed NCT02574390 - Answer ALS: Individualized Initiative for ALS Discovery
Recruiting NCT06012110 - Transcutaneous Electrical Stimulation for Spasticity in Patients With Primary Lateral Sclerosis N/A
Completed NCT00023075 - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis N/A
Enrolling by invitation NCT02327845 - Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Completed NCT00677768 - Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) N/A